echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: busulfan vs systemic radiotherapy plus cyclophosphamide for acute B-lymphoblastic leukemia in adults

    J Clin Oncol: busulfan vs systemic radiotherapy plus cyclophosphamide for acute B-lymphoblastic leukemia in adults

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In patients with acute lymphoblastic leukemia (ALL) who have received allogeneic hematopoietic stem cell transplantation (allo-HSCT), the compatibility of the lebucannum-based protocol with the systemic radiation (TBI)-based protocol remains controversial


    This is an open-labeled, randomized Phase 3 clinical trial jointly conducted by 13 hospitals in China, recruiting ALL patients



    Between January 2016 and February 2020, 275 patients were assigned to each of the two groups, with 273 in the BuCy group and 272 in the TBI-Cy group included in the assessment


    In summary, for adult patients with B-cell ALL who intend to receive HLA-matched allo-HSCT for the standard risk of obtaining the first complete remission, the BuCy protocol has a non-inferior effect and safety profile


    Original Source:

    Haiyan Zhang, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.